Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAmortizatization of IntangiblesAsset Writedowns and ImpairmentAsset Writedowns and ImpairmentCapital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Account PayablesChange in Account PayablesChange in Accured ExpensesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in InventoryChange in ReceivablesChange in ReceivablesDepreciation & Amortization (CF)Depreciation & Amortization (CF)Exchange Rate EffectExchange Rate EffectFree Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesNet Cash FlowNet Cash FlowNet IncomeNon-cash ItemsNon-cash ItemsOther Working Capital ChangesOther Working Capital ChangesOther financing activitiesOther financing activitiesShare-based CompensationShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

RxSight (RXST) Cash from Financing Activities (2020 - 2026)

RxSight filings provide 6 years of Cash from Financing Activities readings, the most recent being $1.1 million for Q4 2025.

  • On a quarterly basis, Cash from Financing Activities fell 64.28% to $1.1 million in Q4 2025 year-over-year; TTM through Dec 2025 was $1.9 million, a 98.49% decrease, with the full-year FY2025 number at $1.9 million, down 98.49% from a year prior.
  • Cash from Financing Activities hit $1.1 million in Q4 2025 for RxSight, up from -$530000.0 in the prior quarter.
  • In the past five years, Cash from Financing Activities ranged from a high of $120.5 million in Q3 2021 to a low of -$8.2 million in Q3 2023.
  • Median Cash from Financing Activities over the past 5 years was $1.6 million (2025), compared with a mean of $16.5 million.
  • Biggest five-year swings in Cash from Financing Activities: skyrocketed 231721.15% in 2021 and later plummeted 1709.67% in 2023.
  • RxSight's Cash from Financing Activities stood at $404000.0 in 2021, then surged by 1461.14% to $6.3 million in 2022, then plummeted by 43.52% to $3.6 million in 2023, then decreased by 16.45% to $3.0 million in 2024, then tumbled by 64.28% to $1.1 million in 2025.
  • The last three reported values for Cash from Financing Activities were $1.1 million (Q4 2025), -$530000.0 (Q3 2025), and $2.1 million (Q2 2025) per Business Quant data.